VJHemOnc Podcast

Acute leukemia experts Noelle Frey, Bianca Santomasso, and Wendy Stock discuss topics such as treatment improvements, CAR T-cell therapy outcomes and toxicities, and the importance of problem definition in acute leukemia. They also address the use of new agents like inotuzumab and the grading of neurologic toxicity. This podcast provides valuable insights into the advancements and challenges in managing acute leukemia.

World-class lymphoma experts Anas Younes and Caron Jacobson discuss key updates on CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma. They explore challenges and benefits, including drug screening, biomarker-driven trials, accessing CAR T-cell therapy, novel drugs like Brute NIB and anti-CD-79 conjugated antibody, studying bridging therapy, understanding T cell composition, and the impact of CAR T-cell therapy on patient enrollment and disease control.

Jens Lohr, Doctor at the Dana-Farber Cancer Institute, Boston, discusses the promising prospects of emerging technologies for MRD testing in multiple myeloma. The podcast covers advancements in single cell sequencing, mass spectrometry, and VDJ sequencing. The clinical applications of DNA markers are also explored, along with the potential impact of MRD testing on myeloma outcomes.

Andrew Spencer and Ravi Vij discuss the current landscape of CAR T-cell therapy in myeloma, exploring targets, payment models, treatment sequence, and the future prospects of this revolutionary treatment.

Deborah Sims, a CLL patient and advocate, and Brian Koffman, MD, founder and medical director of the CLL society, discuss their experiences with the disease, CAR T-cell toxicity and efficacy, the use of measurable residual disease as an indicator of treatment success, and the future of CLL treatment.

Experts from leading cancer centers discuss the current landscape and future of CLL therapies, including challenges in sequencing and managing Richter's transformation. They debate the efficacy of Cartesal therapy and explore combination therapies with novel agents in treating CLL. Updates on ongoing trials and promising results are also discussed.

Experts in CAR T-cell therapy discuss the challenges and advancements in the field. Topics include longer follow-up and reversible side effects in the Zuma One trial, promising data in myeloma, complications and management of cytokine release syndrome, strategies for improvement, and the potential of CAR T-cell therapy in diffuse large B cell lymphoma.

Experts from various institutions discuss Measurable Residual Disease (MRD) in the field of hemonc. They explore the role of MRD as a prognostic factor, novel technologies for MRD detection, and MRD measurement as a strategy for treatment-free survival. Recorded at several conferences, this podcast dives into the exciting realm of MRD in cancer management.

Mark Levis and Ari Melnick discuss the implications of genomic data for the management of acute leukemias, including the role of the epigenome, the use of artificial intelligence in data analysis, and the exploration of pre-leukemic clones. They also touch on the challenges in leukemia classification and treatment, as well as the potential of personalized medicine and biomarkers in AML management.

Experts discuss the controversies surrounding the use of minimal residual disease (MRD) in the management of acute leukemias, including its potential as a prognostic marker and measure of disease. They explore the preferred techniques for MRD measurement in the US and Europe, as well as the possibility of combining flow cytometry and next-generation sequencing for MRD assessment. The podcast also delves into the challenges of eradicating MRD and the importance of utilizing phenotyping and MRD analysis in personalized treatment strategies for acute leukemias.